Browsing Tag
Icovamenib
1 post
Biomea Fusion reports positive 52-week phase II results showing non-chronic icovamenib treatment benefits in type 2 diabetes
Find out how Biomea Fusion’s 52-week phase II results point to a regenerative, non-chronic path for type 2 diabetes treatment.